14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
KROS vs LYRA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Keros Therapeutics, Inc. (KROS) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). KROS carries a Unified Composite Score of 52.2/100 (HOLD) at $11.16 (48.8x Forward P/E, -172.4% operating margin), whereas LYRA carries 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin).
Technical & Structure Timing Caution: KROS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 56.1); meanwhile LYRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $2.3M market capitalization and -25032.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ KROS vs LYRA Key Questions & Quantitative Answers
As of Nov 17, 2026, Keros Therapeutics, Inc. (KROS) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). KROS carries a Unified Composite Score of 52.2/100 (HOLD) at $11.16 (48.8x Forward P/E, -172.4% operating margin), whereas LYRA carries 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin). Technical & Structure Timing Caution: KROS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 56.1); meanwhile LYRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
KROS leads the Growth & Scale pillar: KROS posts +180.5% YoY revenue growth and +0.0% YoY earnings growth on $41M TTM revenue (-82.4% gross margin, -172.4% operating margin), compared with LYRA at -87.2% YoY revenue growth and +0.0% YoY earnings growth on $600,000 TTM revenue (N/A gross margin, -25032.0% operating margin). Across the 6-period historical trajectory (FY2019 to FY2025), KROS cumulative revenue shifted +2300.0% while LYRA shifted N/A. In operating R&D and SG&A reinvestment, KROS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LYRA.
KROS screens cheaper on headline valuation multiples. KROS trades at 48.8x Forward P/E, 48.8x Trailing P/E, N/M PEG, and N/M EV/Revenue (-118.4% FCF margin), whereas LYRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KROS (-12.6% ROE) versus LYRA (-404.5% ROE) capital efficiency.
In options market volatility and institutional positioning, KROS carries 60.8% implied volatility (10th %ile, Compressed (<25th %ile)), a 7.00x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.11β · 67% Vol realized risk). By comparison, LYRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.33β · 248% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.